Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Systemic Therapy
100%
Clinical Practice Guidelines
100%
American Society of Clinical Oncology
100%
Clinical Oncology
100%
Human Epidermal Growth Factor Receptor 2-targeted Therapy
100%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (HER2-positive breast cancer)
100%
T-DM1
80%
Survival Benefit
60%
Human Epidermal Growth Factor Receptor 2 (HER2)
60%
Progression-free Survival
60%
Advanced Breast Cancer
60%
Endocrine Therapy
60%
Pertuzumab
60%
Trastuzumab
40%
Second-line Treatment
40%
Treatment Lines
40%
Breast Cancer
20%
Patient Selection
20%
Docetaxel
20%
Progesterone Receptor
20%
Congestive Heart Failure
20%
Adverse Events
20%
Maximum Response
20%
Estrogen Receptor-positive
20%
Oncologists
20%
Taxanes
20%
Medical Oncology
20%
Radiation Oncology
20%
First-line Therapy
20%
Systematic Literature Review
20%
Left Ventricular Ejection Fraction
20%
Optimal Duration
20%
Overall Survival Progression-free Survival
20%
Combination of Therapies
20%
Chemotherapy Duration
20%
Evidence-based Recommendations
20%
Review Criteria
20%
Guideline Implementation
20%
Cleopatra
20%
Trastuzumab Emtansine
20%
Survival Event
20%
Oncology Guidelines
20%
EMILIA
20%
Medicine and Dentistry
Systemic Therapy
100%
Clinical Oncology
100%
Epidermal Growth Factor Receptor 2
100%
Gamma Urogastrone
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Targeted Therapy
62%
Progression Free Survival
50%
Breast Cancer
37%
Hormone Therapy
37%
Pertuzumab
37%
Clinician
25%
Systematic Review
25%
Trastuzumab
25%
Overall Survival
12%
Adverse Event
12%
Estrogen Receptor
12%
Congestive Heart Failure
12%
Chemotherapy
12%
Docetaxel
12%
Oncologist
12%
Medical Oncology
12%
Radiation Oncology
12%
Heart Left Ventricle Ejection Fraction
12%
Trastuzumab Emtansine
12%
Progesterone Receptor Positive Breast Cancer
12%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor 2
100%
Gamma Urogastrone
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Progression Free Survival
50%
Breast Cancer
37%
Endocrine Therapy
37%
Pertuzumab
37%
Trastuzumab
25%
Overall Survival
12%
Docetaxel
12%
Combination Therapy
12%
Estrogen Receptor
12%
Congestive Heart Failure
12%
Adverse Event
12%
Taxane
12%
Trastuzumab Emtansine
12%
Progesterone Receptor Positive Breast Cancer
12%
Chemotherapy Regimen
12%